Samsara BioCapital LLC Has $2.05 Million Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Samsara BioCapital LLC lessened its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 25.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 147,319 shares of the company's stock after selling 49,106 shares during the period. Day One Biopharmaceuticals comprises 0.4% of Samsara BioCapital LLC's investment portfolio, making the stock its 29th biggest holding. Samsara BioCapital LLC owned about 0.15% of Day One Biopharmaceuticals worth $2,052,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DAWN. FMR LLC increased its position in shares of Day One Biopharmaceuticals by 178.5% in the third quarter. FMR LLC now owns 7,412,380 shares of the company's stock valued at $103,254,000 after buying an additional 4,750,936 shares in the last quarter. Braidwell LP lifted its holdings in Day One Biopharmaceuticals by 60.5% in the 3rd quarter. Braidwell LP now owns 4,873,853 shares of the company's stock worth $67,893,000 after buying an additional 1,837,949 shares in the last quarter. Vestal Point Capital LP increased its stake in shares of Day One Biopharmaceuticals by 100.0% in the third quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company's stock worth $34,825,000 after buying an additional 1,250,000 shares during the last quarter. Deerfield Management Company L.P. Series C grew its position in shares of Day One Biopharmaceuticals by 65.6% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 2,923,137 shares of the company's stock worth $40,281,000 after acquiring an additional 1,157,825 shares in the last quarter. Finally, First Turn Management LLC bought a new stake in shares of Day One Biopharmaceuticals during the 3rd quarter valued at about $13,204,000. 87.95% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have commented on DAWN. TD Cowen raised shares of Day One Biopharmaceuticals to a "strong-buy" rating in a research note on Monday, November 4th. Needham & Company LLC reissued a "buy" rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. Finally, HC Wainwright restated a "buy" rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $35.71.

Day One Biopharmaceuticals Stock Performance

NASDAQ:DAWN traded down $0.45 on Thursday, reaching $13.35. The company's stock had a trading volume of 523,015 shares, compared to its average volume of 960,588. The firm has a market cap of $1.35 billion, a PE ratio of -13.40 and a beta of -1.51. The business's 50-day moving average price is $14.29 and its two-hundred day moving average price is $14.09. Day One Biopharmaceuticals, Inc. has a 1-year low of $11.51 and a 1-year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.58. The company had revenue of $93.76 million during the quarter, compared to analyst estimates of $15.05 million. During the same quarter last year, the company earned ($0.54) EPS. As a group, sell-side analysts expect that Day One Biopharmaceuticals, Inc. will post -0.88 EPS for the current year.

Insider Buying and Selling at Day One Biopharmaceuticals

In related news, insider Samuel C. Blackman sold 11,245 shares of the company's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $16.03, for a total transaction of $180,257.35. Following the sale, the insider now owns 1,085,790 shares in the company, valued at approximately $17,405,213.70. This represents a 1.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold 51,745 shares of company stock valued at $775,867 in the last 90 days. 8.40% of the stock is currently owned by company insiders.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.